Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT ID: NCT05748483
Last Updated: 2025-05-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
545 participants
INTERVENTIONAL
2023-10-07
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Atogepant is a medicine currently approved for the preventive treatment of adult patients with episodic migraine (0 to 14 migraine days per month) and is being studied for the preventative treatment of migraine globally. Topiramate is an approved medication for migraine prevention. This study is conducted in 2 periods. In Period 1, participants will be randomly put into 1 of 2 groups at the start of the study to receive atogepant or topiramate. In Period 2, eligible participants will receive atogepant. Approximately 520 participants aged 18 and older will be enrolled in this study in approximately 85 sites across the world.
Participants will receive atogepant (and placebo for topiramate) or topiramate (and placebo for atogepant) for 24 weeks in Period 1. Both atogepant and placebo for atogepant are given as a tablet to take by mouth while topiramate and placebo for topiramate are given as a capsule to take by mouth. After 24 weeks, all eligible participants will receive atogepant for 52 weeks in Period 2. Participants are monitored for safety for 4 weeks after their last study treatment.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atogepant
Participants will receive atogepant in double-blind period. From Week 25, eligible participants will receive atogepant in open-label period.
Atogepant
Oral Tablet
Placebo for Topiramate
Oral Capsule
Topiramate
Participants will receive topiramate in double-blind period. From Week 25, eligible participants will receive atogepant in open-label period.
Atogepant
Oral Tablet
Placebo for Atogepant
Oral Tablet
Topiramate
Oral Capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atogepant
Oral Tablet
Placebo for Atogepant
Oral Tablet
Topiramate
Oral Capsule
Placebo for Topiramate
Oral Capsule
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of \>= 4 migraine days per month who require preventive treatment of migraine and are eligible for conventional migraine prophylaxis.
Exclusion Criteria
* Have clinically significant cardiovascular, cerebrovascular, hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Universitaet Innsbruck /ID# 247213
Innsbruck, Tyrol, Austria
Konventhospital Barmherzige Brueder Linz /ID# 247217
Linz, Upper Austria, Austria
Medizinische Universitaet Wien /ID# 247119
Vienna, Vienna, Austria
Universitair Ziekenhuis Brussel /ID# 246959
Jette, Brussels Capital, Belgium
Jessa Ziekenhuis /ID# 246954
Hasselt, Limburg, Belgium
UZ Gent /ID# 246957
Ghent, Oost-Vlaanderen, Belgium
AZ Sint-Jan Brugge /ID# 246962
Bruges, , Belgium
CHR de la Citadelle /ID# 246964
Liège, , Belgium
Vancouver Island Health Authority /ID# 247733
Victoria, British Columbia, Canada
Maritime Neurology /ID# 247728
Halifax, Nova Scotia, Canada
Aggarwal and Associates Limited /ID# 247727
Brampton, Ontario, Canada
CCR Ostrava, s.r.o. /ID# 245924
Ostrava, Ostrava-mesto, Czechia
A-Shine s.r.o. /ID# 245923
Pilsen, Plzeň Region, Czechia
Praglandia /ID# 247511
Prague, Praha 5, Czechia
NeuroHK s.r.o. /ID# 247500
Hradec Králové, , Czechia
Pratia Pardubice a.s. /ID# 249017
Pardubice, , Czechia
Clintrial s.r.o. /ID# 245926
Prague, , Czechia
Pratia Prague s.r.o. /ID# 245925
Prague, , Czechia
Fakultni Thomayerova nemocnice /ID# 249016
Prague, , Czechia
INEP medical s.r.o. /ID# 245927
Prague, , Czechia
Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 247562
Bron, Rhone, France
CHU Clermont Ferrand - Hopital Gabriel Montpied /ID# 247561
Clermont-Ferrand, , France
AP-HP - Groupe Hospitalier 10e - Hopital Lariboisiere /ID# 249244
Paris, , France
Studienzentrum fuer Neurologie und Psychiatrie /ID# 249236
Böblingen, Baden-Wurttemberg, Germany
Universitaetsklinikum Tuebingen /ID# 246043
Tübingen, Baden-Wurttemberg, Germany
Neuropoint GmbH /ID# 246038
Ulm, Baden-Wurttemberg, Germany
Neuropraxis Muenchen Sued /ID# 246045
Unterhaching, Bavaria, Germany
Gesundheitszentrum Hoppegarten /ID# 249242
Hoppegarten, Brandenburg, Germany
Praxis fuer Neurologie, Psychiatrie und Psychotherapie /ID# 248427
Bad Homburg, Hesse, Germany
Kopfschmerzzentrum - Frankfurt /ID# 248686
Frankfurt am Main, Hesse, Germany
Klinische Forschung Hannover-Mitte GmbH /ID# 248565
Hanover, Lower Saxony, Germany
Studienzentrum Nord-West /ID# 246039
Westerstede, Lower Saxony, Germany
Klinische Forschung Schwerin GmbH /ID# 248074
Schwerin, Mecklenburg-Vorpommern, Germany
ZNS Siegen /ID# 251180
Siegen, North Rhine-Westphalia, Germany
Krankenhaus der Barmherzigen Brüder Trier /ID# 248564
Trier, Rhineland-Palatinate, Germany
Pharmakologisches Studienzentrum Chemnitz GmbH /ID# 246030
Chemnitz, Saxony, Germany
Universitaetsklinikum Carl Gustav Carus Dresden /ID# 246040
Dresden, Saxony, Germany
Ambenet Hausarztpraxis /ID# 246028
Leipzig, Saxony, Germany
Schmerzklinik Kiel /ID# 246037
Kiel, Schleswig-Holstein, Germany
Neurologisches Facharztzentrum Berlin /ID# 248064
Berlin, , Germany
Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 246029
Berlin, , Germany
NeuroZentrum Bielefeld /ID# 250758
Bielefeld, , Germany
Neuro Centrum Odenwald /ID# 248067
Erbach im Odenwald, , Germany
Universitaetsklinikum Essen /ID# 246033
Essen, , Germany
Universitaetsmedizin Greifswald /ID# 248574
Greifswald, , Germany
Klinische Forschung Hamburg GmbH /ID# 248620
Hamburg, , Germany
Neurologische Gemeinschaftspraxis Kassel und Vellmar /ID# 248085
Kassel, , Germany
Lewis Neurologie /ID# 250498
Stuttgart, , Germany
MIND Clinic /ID# 247867
Budapest, , Hungary
Clinexpert Kft /ID# 247868
Budapest, , Hungary
Semmelweis Egyetem /ID# 248428
Budapest, , Hungary
S-Medicon Kft /ID# 247682
Budapest, , Hungary
Debreceni Egeszsegugyi Kozpontja /ID# 247549
Debrecen, , Hungary
Meir Medical Center /ID# 247261
Kfar Saba, Central District, Israel
Hillel Yaffe Medical Center /ID# 247258
Hadera, H_efa, Israel
Shaare Zedek Medical Center /ID# 247259
Jerusalem, Jerusalem, Israel
Soroka University Medical Center /ID# 247260
Beersheba, Southern District, Israel
Azienda Ospedaliero Universitaria Careggi /ID# 247575
Florence, Firenze, Italy
Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 247576
Naples, Napoli, Italy
IRCCS San Raffaele /ID# 247573
Rome, Roma, Italy
Azienda Ospedaliero-Universitaria di Modena /ID# 247578
Modena, , Italy
Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS /ID# 247579
Pavia, , Italy
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 247580
Roma, , Italy
Solumed Centrum Medyczne /ID# 247317
Poznan, Greater Poland Voivodeship, Poland
Clinical Research Center Sp. z.o.o. Medic-R sp. k /ID# 247323
Poznan, Greater Poland Voivodeship, Poland
Vitamed Galaj i Cichomski Sp.j. /ID# 247314
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Athleticomed Sp. z o.o /ID# 250790
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Instytut Zdrowia Dr Boczarska Jedynak /ID# 247315
Oświęcim, Lesser Poland Voivodeship, Poland
Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej /ID# 247298
Lublin, Lublin Voivodeship, Poland
RCMed Oddzial Sochaczew /ID# 247378
Sochaczew, Masovian Voivodeship, Poland
ETG Neuroscience Sp. z o.o. /ID# 247331
Warsaw, Masovian Voivodeship, Poland
Silmedic Sp. z o.o. /ID# 247376
Katowice, Silesian Voivodeship, Poland
Hospital Garcia de Orta /ID# 247163
Almada, Setúbal District, Portugal
2CA-Braga, Hospital de Braga /ID# 247165
Braga, , Portugal
Hospital da Luz Lisboa /ID# 247168
Lisbon, , Portugal
Unidade Local de Saude de Santa Maria, EPE /ID# 247167
Lisbon, , Portugal
Hospital Prof. Doutor Fernando Fonseca, EPE /ID# 247172
Lisbon, , Portugal
Unidade Local de Saúde de Matosinhos, EPE /ID# 247169
Matosinhos Municipality, , Portugal
The Adam Practice /ID# 248880
Poole, Dorset, United Kingdom
Duplicate_NHS Greater Glasgow and Clyde /ID# 247979
Glasgow, Scotland, United Kingdom
West Walk Surgery /ID# 252855
Bristol, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-501172-25-00
Identifier Type: OTHER
Identifier Source: secondary_id
M22-061
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.